Home > A. Molecular pathology > Targeted therapy > Small molecules > apatinib
apatinib
Tuesday 1 November 2016
YN968D1
| WKP |
Apatinib is a VEGFR2 tyrosine kinase inhibitor (VEGFR2 TKI) that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR).
Apatinib is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells.
Specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases, as a TKI.
Apatinib is an investigational cancer drug currently undergoing clinical trials as a potential targeted treatment in:
metastatic gastric carcinomas,
metastatic mammary carcinomas
advanced hepatocellular carcinoma (HCC)
